JNJ · Full Picture

JOHNSON & JOHNSON — the full picture

Earnings window · 2026-07-02 to 2026-09-24 · anchored on the 10-Q report

One earnings window, everything merged: the filing, the call, press releases and news digests, folded into ranked threads.

What to look at first

  1. Talc Litigation Settlement · Litigation & settlementsPriority 84
    -10.9% operating_income; 3 sources (news, press_release, sec_filing); 6 forward row(s); structured_verified
    Johnson & Johnson has agreed to a $5.5 billion settlement to resolve tens of thousands of talc baby powder lawsuits.
  2. Revenue Performance and Mix · Revenue growth & mixPriority 83
    +32.1% revenue (realized); 3 sources (news, press_release, sec_filing); 2 forward row(s); structured_verified
    Analysts project Johnson & Johnson Q2 2026 EPS of $2.83 and revenue of $25.01 billion.
  3. Accrued Legal and Regulatory · Regulatory action & investigationsPriority 82
    -2.7% liability; 2 sources (news, sec_filing); 3 forward row(s); structured_verified
    The Company anticipates using operating cash flows, ability to raise funds, credit facilities and commercial paper markets to fund operating needs including remaining balance of approximately $3.7 billion related to talc matters, $1.7 billion related to the current portion of Corporate bonds due and approximately $0.9 billion related to opioid settlements.
  4. Guidance / Outlook · Guidance & outlookPriority 82
    +44.6% revenue; 2 sources (news, press_release); 13 forward row(s); quote_verified
    Company increased 2026 estimated reported sales guidance to a midpoint of $101.1 billion, representing a 7.3% change vs prior year at the midpoint
  5. Acquisition / Partnership / Divestiture · M&A and divestituresPriority 73
    -0.3% cash; 2 sources (news, press_release); 10 forward row(s); quote_verified
    Johnson & Johnson secured an exclusive option to acquire Sail Biomedicines for an additional $2.58 billion, bringing the potential total value to $3.5 billion.
  6. Headcount / Restructuring · Restructuring & impairmentPriority 72
    -4.7% operating_income; 2 sources (news, sec_filing); 3 forward row(s); structured_verified
    In the fiscal second quarter of 2026, the Company initiated a supply chain restructuring program primarily in the Innovative Medicine segment to exit certain manufacturing locations; the program is expected to be substantially complete by the end of 2029 with estimated costs between $650 million and $750 million.
  7. Immunology Competition Pressure · Competition & market sharePriority 70
    -7.4% revenue (realized); 2 sources (news, sec_filing); 1 forward row(s); quote_verified
    STELARA sales were $1,396 million for the fiscal six months ended June 28, 2026 versus $3,278 million prior year, a total decline of 57.4% and an operational decline of 58.7%.
  8. Orthopaedics Separation · UnclassifiedPriority 68
    2 sources (news, sec_filing); 1 forward row(s); quote_verified
    The Company announced in October 2025 its intention to separate its Orthopaedics business and continues to explore multiple paths with a targeted completion within 18 to 24 months after the initial announcement.
  9. Segment Profitability · Operating income & profitabilityPriority 67
    -29.6% operating_income (realized); structured_verified
    Consolidated earnings before provision for taxes on income for the fiscal six months of 2026 was $12.7 billion representing 25.8% of sales as compared to $20.1 billion in the fiscal six months of 2025 representing 44.1% of sales.
  10. DePuy Synthes Divestiture · M&A and divestituresPriority 66
    -5.5% revenue; 5 forward row(s); quote_verified
    Johnson & Johnson is reportedly close to selling its DePuy Synthes orthopedics business to Apollo Equity Management for approximately $20 billion.
  11. Capital Return Program · Buybacks & dividendsPriority 65
    2 sources (news, sec_filing); 2 forward row(s); quote_verified
    TIKR projects Johnson & Johnson free cash flow for 2026 of $21 billion and reports the company's payout ratio decreased from 84% to 46% while its near-term dividend yield compressed to 2%.
  12. Regulatory Approval Milestones · Regulatory action & investigationsPriority 62
    2 sources (news, press_release); 6 forward row(s); quote_verified
    The CHMP recommendation would make Icotyde the first oral IL-23 drug to market, and it is projected to be a multi-billion dollar brand.

Threads by pillar

Revenue & Demand Priority 91 · 9 threads

Costs & Margins Priority 80 · 4 threads

Capital & Balance Sheet Priority 77 · 5 threads

Strategy & Portfolio Priority 83 · 9 threads

Legal, Regulatory & Policy Priority 91 · 6 threads

Guidance & Outlook Priority 82 · 1 thread

Macro & Market Conditions Priority 75 · 4 threads

Management & Governance Priority 28 · 1 thread

Unclassified Priority 88 · 5 threads

Expected impact by metric

metricforward netforward grossrealized
revenue+42.1%+53.0%+26.6%
operating_income-20.4%+20.4%-32.8%
liability-4.4%+4.4%—
net_income-3.4%+3.4%-52.5%
cash+2.6%+3.3%-6.5%
assets+1.7%+1.7%+12.1%
margin——-0.6%